TCGA-96-A4JL-01A-11R-A24Z-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 78
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.540
- ALLOGRAFT_REJECTION+0.450
- INTERFERON_GAMMA_RESPONSE+0.450
- E2F_TARGETS+0.390
- G2M_CHECKPOINT+0.360
- MYC_TARGETS_V2+0.350
- HEDGEHOG_SIGNALING+0.330
- WNT_BETA_CATENIN_SIGNALING+0.300
- MITOTIC_SPINDLE+0.260
- MYC_TARGETS_V1+0.230
Top 10 suppressed
- CHOLESTEROL_HOMEOSTASIS-0.530
- HYPOXIA-0.440
- COAGULATION-0.380
- FATTY_ACID_METABOLISM-0.380
- GLYCOLYSIS-0.350
- ANGIOGENESIS-0.340
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.340
- ADIPOGENESIS-0.320
- OXIDATIVE_PHOSPHORYLATION-0.300
- PEROXISOME-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8613797 | — | D | 0.871 |
| 2 | TCGA-56-8307-01A-11R-2296-07 | — | cohortSQ1 | 0.834 |
| 3 | C3N-00497 | — | cohortSQ1 | 0.833 |
| 4 | AUR-AE6Y-TTP1-A-1-0-R-A741-41 | — | D | 0.828 |
| 5 | SRR5088835 | — | — | 0.828 |
| 6 | SRR6013475 | — | cohortMD2 | 0.825 |
| 7 | AUR-AFEA-TTM6-A-1-0-R-A741-41 | — | D | 0.818 |
| 8 | TCGA-B6-A0RT-01A-21R-A084-07 | — | D | 0.816 |
| 9 | SRR1313149 | — | D | 0.812 |
| 10 | SRR8942983 | — | — | 0.812 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.540 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.450 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.450 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.390 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.360 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.350 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.330 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.300 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.260 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.230 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.180 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.140 | Temsirolimus | — uncovered |
| DNA_REPAIR | 0.110 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.070 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.060 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.030 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.030 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.020 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.020 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.020 | Idelalisib | — uncovered |